Minimal Residual Disease Detection in Mantle Cell Lymphoma: Technical Aspects and Clinical Relevance

Seminars in Hematology

Volumn 48, Issue 3, 2011, Pages 172-184

  Pott, Christiane ^a  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

CARMUSTINE; CISPLATIN; CYCLOPHOSPHAMIDE; CYTARABINE; DEXAMETHASONE; DOXORUBICIN; ETOPOSIDE; FLUDARABINE; MELPHALAN; PREDNISONE; RITUXIMAB; VINCRISTINE;

ARTICLE; AUTOLOGOUS HEMATOPOIETIC STEM CELL TRANSPLANTATION; CLINICAL TRIAL (TOPIC); DRUG DOSE ESCALATION; DRUG MEGADOSE; FLOW CYTOMETRY; INTERMETHOD COMPARISON; MANTLE CELL LYMPHOMA; MINIMAL RESIDUAL DISEASE; MOLECULARLY TARGETED THERAPY; MULTIPLE CYCLE TREATMENT; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; PROGNOSIS; RISK ASSESSMENT; TREATMENT RESPONSE; WHOLE BODY RADIATION;

FEMALE; FLOW CYTOMETRY; HUMANS; LYMPHOMA, MANTLE-CELL; MALE; NEOPLASM, RESIDUAL; POLYMERASE CHAIN REACTION;

EID: 79960487924     PISSN: 00371963     EISSN: 15328686     Source Type: Journal    
DOI: 10.1053/j.seminhematol.2011.05.002     Document Type: Article

References (81)

1. Cheson B.D., Pfistner B., Juweid M.E., et al. Revised response criteria for malignant lymphoma. J Clin Oncol 2007, 25:579-586.
2. Andersen N.S., Pedersen L., Elonen E., et al. Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant. Eur J Haematol 2003, 71:73-80.
3. Dreyling M., Lenz G., Hoster E., et al. Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the European MCL Network. Blood 2005, 105:2677-2684.
4. Vandenberghe E., Ruiz de Elvira C., Loberiza F.R., et al. Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries. Br J Haematol 2003, 120:793-800.
5. Geisler C.H., Kolstad A., Laurell A., et al. Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group. Blood 2008, 112:2687-2693.
6. Bosch F., Ferrer A., Villamor N., et al. Fludarabine, cyclophosphamide, and mitoxantrone as initial therapy of chronic lymphocytic leukemia: high response rate and disease eradication. Clin Cancer Res 2008, 14:155-161.
7. Bruggemann M., Raff T., Flohr T., et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. Blood 2006, 107:1116-1123.
8. Ladetto M., Corradini P., Vallet S., et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002, 100:1559-1565.
9. Pott C., Schrader C., Gesk S., et al. Quantitative assessment of molecular remission after high-dose therapy with autologous stem cell transplantation predicts long-term remission in mantle cell lymphoma. Blood 2006, 107:2271-2278.
10. Raff T., Gokbuget N., Luschen S., et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. Blood 2007, 109:910-915.
11. Bruggemann M., Pott C., Ritgen M., Kneba M. Significance of minimal residual disease in lymphoid malignancies. Acta Haematol 2004, 112:111-119.
12. Foroni L., Coyle L.A., Papaioannou M., et al. Molecular detection of minimal residual disease in adult and childhood acute lymphoblastic leukaemia reveals differences in treatment response. Leukemia 1997, 11:1732-1741.
13. Mortuza F.Y., Papaioannou M., Moreira I.M., et al. Minimal residual disease tests provide an independent predictor of clinical outcome in adult acute lymphoblastic leukemia. J Clin Oncol 2002, 20:1094-1104.
14. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005, 23:2971-2979.
15. Vidriales M.B., Perez J.J., Lopez-Berges M.C., et al. Minimal residual disease in adolescent (older than 14 years) and adult acute lymphoblastic leukemias: early immunophenotypic evaluation has high clinical value. Blood 2003, 101:4695-4700.
16. Neale G.A.M., Coustan-Smith E., Stow P., et al. Comparative analysis of flow cytometry and polymerase chain reaction for the detection of minimal residual disease in childhood acute lymphoblastic leukemia. Leukemia 2004, 18:934-938.
17. Dworzak M.N., Froschl G., Printz D., et al. Prognostic significance and modalities of flow cytometric minimal residual disease detection in childhood acute lymphoblastic leukemia. Blood 2002, 99:1952-1958.
18. Moreton P., Kennedy B., Lucas G., et al. Eradication of minimal residual disease in B-cell chronic lymphocytic leukemia after alemtuzumab therapy is associated with prolonged survival. J Clin Oncol 2005, 23:2971-2979.
19. Bottcher S., Ritgen M., Buske S., et al. Minimal residual disease detection in mantle cell lymphoma: methods and significance of four-color flow cytometry compared to consensus IGH-polymerase chain reaction at initial staging and for follow-up examinations. Haematologica 2008, 93:551-559.
20. Bottcher S., Ritgen M., Pott C., et al. Comparative analysis of minimal residual disease detection using four-color flow cytometry, consensus IgH-PCR, and quantitative IgH PCR in CLL after allogeneic and autologous stem cell transplantation. Leukemia 2004, 18:1637-1645.
21. Rawstron A.C., Kennedy B., Evans P.A.S., et al. Quantitation of minimal disease levels in chronic lymphocytic leukemia using a sensitive flow cytometric assay improves the prediction of outcome and can be used to optimize therapy. Blood 2001, 98:29-35.
22. Sanchez M.L., Almeida J., Vidriales B., et al. Incidence of phenotypic aberrations in a series of 467 patients with B chronic lymphoproliferative disorders: basis for the design of specific four-color stainings to be used for minimal residual disease investigation. Leukemia 2002, 16:1460-1469.
23. Costa E.S., Pedreira C.E., Barrena S., et al. Automated pattern-guided principal component analysis vs expert-based immunophenotypic classification of B-cell chronic lymphoproliferative disorders: a step forward in the standardization of clinical immunophenotyping. Leukemia 2010, 24:1927-1933.
24. Brizova H., Kalinova M., Krskova L., Mrhalova M., Kodet R. Quantitative monitoring of cyclin D1 expression: a molecular marker for minimal residual disease monitoring and a predictor of the disease outcome in patients with mantle cell lymphoma. Int J Cancer 2008, 123:2865-2870.
25. Evans P.A.S., Pott C., Groenen P.J.T.A., et al. Significantly improved PCR-based clonality testing in B-cell malignancies by use of multiple immunoglobulin gene targets. Report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2006, 21(2):207-214.
26. van Dongen J.J., Wolvers-Tettero I.L. Analysis of immunoglobulin and T cell receptor genes. Part II: possibilities and limitations in the diagnosis and management of lymphoproliferative diseases and related disorders. Clin Chim Acta 1991, 198:93-174.
27. van Dongen J.J., Wolvers-Tettero I.L. Analysis of immunoglobulin and T cell receptor genes. Part I: Basic and technical aspects. Clin Chim Acta 1991, 198:1-91.
28. van Krieken J.H.J.M., Langerak A.W., Macintyre E.A., et al. Improved reliability of lymphoma diagnostics via PCR-based clonality testing-report of the BIOMED-2 Concerted Action BHM4-CT98-3936. Leukemia 2006, 21:201-206.
29. Kurokawa T., Kinoshita T., Murate T., et al. Complementarity determining region-III is a useful molecular marker for the evaluation of minimal residual disease in mantle cell lymphoma. Br J Haematol 1997, 98:408-412.
30. van Dongen J.J., Langerak A.W., Bruggemann M., et al. Design and standardization of PCR primers and protocols for detection of clonal immunoglobulin and T-cell receptor gene recombinations in suspect lymphoproliferations: report of the BIOMED-2 Concerted Action BMH4-CT98-3936. Leukemia 2003, 17:2257-2317.
31. Aubin J., Davi F., Nguyen-Salomon F., et al. Description of a novel FR1 IgH PCR strategy and its comparison with three other strategies for the detection of clonality in B cell malignancies. Leukemia 1995, 9(3):471-479.
32. Linke B., Pyttlich J., Tiemann M., et al. Identification and structural analysis of rearranged immunoglobulin heavy chain genes in lymphomas and leukemias. Leukemia 1995, 9:840-847.
33. Kienle D., Krober A., Katzenberger T., et al. VH mutation status and VDJ rearrangement structure in mantle cell lymphoma: correlation with genomic aberrations, clinical characteristics, and outcome. Blood 2003, 102:3003-3009.
34. Walsh S.H., Thorselius M., Johnson A., et al. Mutated VH genes and preferential VH3-21 use define new subsets of mantle cell lymphoma. Blood 2003, 101:4047-4054.
35. Bruggemann M., Droese J., Bolz I., et al. Improved assessment of minimal residual disease in B cell malignancies using fluorogenic consensus probes for real-time quantitative PCR. Leukemia 2000, 14:1419-1425.
36. van der Velden V.H., Hochhaus A., Cazzaniga G., et al. Detection of minimal residual disease in hematologic malignancies by real-time quantitative PCR: principles, approaches, and laboratory aspects. Leukemia 2003, 17:1013-1034.
37. van der Velden V.H.J., Cazzaniga G., Schrauder A., et al. Analysis of minimal residual disease by Ig//TCR gene rearrangements: guidelines for interpretation of real-time quantitative PCR data. Leukemia 2007, 21:604-611.
38. Pott C., Tiemann M., Linke B., et al. Structure of Bcl-1 and IgH-CDR3 rearrangements as clonal markers in mantle cell lymphomas. Leukemia 1998, 12:1630-1637.
39. Pott C., Hoster E., Delfau-Larue M.H., et al. Molecular remission is an independent predictor of clinical outcome in patients with mantle cell lymphoma after combined immunochemotherapy: a European MCL intergroup study. Blood 2010, 115:3215-3223.
40. Andersen N.S., Donovan J.W., Borus J.S., et al. Failure of immunologic purging in mantle cell lymphoma assessed by polymerase chain reaction detection of minimal residual disease. Blood 1997, 90:4212-4221.
41. Andersen N.S., Donovan J.W., Zuckerman A., et al. Real-time polymerase chain reaction estimation of bone marrow tumor burden using clonal immunoglobulin heavy chain gene and bcl-1/JH rearrangements in mantle cell lymphoma. Exp Hematol 2002, 30:703-710.
42. van der Velden V.H., de Bie M., Van Wering E.R., van Dongen J.J. Immunoglobulin light chain gene rearrangements in precursor-B-acute lymphoblastic leukemia: characteristics and applicability for the detection of minimal residual disease. Haematologica 2006, 91:679-682.
43. Gribben J.G., Neuberg D., Freedman A.S., et al. Detection by polymerase chain reaction of residual cells with the bcl-2 translocation is associated with increased risk of relapse after autologous bone marrow transplantation for B-cell lymphoma. Blood 1993, 81:3449-3457.
44. Rosenberg C.L., Wong E., Petty E.M., et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci U S A 1991, 88:9638-9642.
45. Williams M.E., Swerdlow S.H. Cyclin D1 overexpression in non-Hodgkin's lymphoma with chromosome 11 bcl-1 rearrangement. Ann Oncol 1994, 5(Suppl 1):71-73.
46. Siebert R., Matthiesen P., Harder S., et al. Application of interphase cytogenetics for the detection of t(11;14)(q13;q32) in mantle cell lymphomas. Ann Oncol 1998, 9:519-526.
47. Tsujimoto Y., Yunis J., Onorato-Showe L., et al. Molecular cloning of the chromosomal breakpoint of B-cell lymphomas and leukemias with the t(11;14) chromosome translocation. Science 1984, 224:1403-1406.
48. Williams M.E., Meeker T.C., Swerdlow S.H. Rearrangement of the chromosome 11 bcl-1 locus in centrocytic lymphoma: analysis with multiple breakpoint probes. Blood 1991, 78:493-498.
49. Williams M.E., Zukerberg L.R., Harris N.L., et al. Mantle cell/centrocytic lymphoma: molecular and phenotypic analysis including analysis of the bcl-1 major translocation cluster by PCR. Curr Top Microbiol Immunol 1995, 194:341-346.
50. Williams M.E., Swerdlow S.H., Rosenberg C.L., Arnold A. Characterization of chromosome 11 translocation breakpoints at the bcl-1 and PRAD1 loci in centrocytic lymphoma. Cancer Res 1992, 52(Suppl):5541s-5544s.
51. Rimokh R., Berger F., Delsol G., et al. Detection of the chromosomal translocation t(11;14) by polymerase chain reaction in mantle cell lymphomas. Blood 1994, 83:1871-1875.
52. Rimokh R., Berger F., Delsol G., et al. Rearrangement and overexpression of the BCL-1/PRAD-1 gene in intermediate lymphocytic lymphomas and in t(11q13)-bearing leukemias. Blood 1993, 81:3063-3067.
53. Rimokh R., Berger F., Bastard C., et al. Rearrangement of CCND1 (BCL1/PRAD1) 3' untranslated region in mantle- cell lymphomas and t(11q13)-associated leukemias. Blood 1994, 83:3689-3696.
54. Swerdlow S.H., Campo E., Seto M., Müller-Hermelink H.K. Mature B-cell neoplasms: mantle cell lymphoma. WHO classification of tumours of haematopoietic and lymphoid tissues 2008, 229-232. IARC Press, Lyon, France.
55. Swerdlow S.H., Williams M.E. From centrocytic to mantle cell lymphoma: a clinicopathologic and molecular review of 3 decades. Hum Pathol 2002, 33:7-20.
56. Voena C., Ladetto M., Astolfi M., et al. A novel nested-PCR strategy for the detection of rearranged immunoglobulin heavy-chain genes in B cell tumors. Leukemia 1997, 11:1793-1798.
57. Olsson K., Gerard C.J., Zehnder J., et al. Real-time t(11;14) and t(14;18) PCR assays provide sensitive and quantitative assessments of minimal residual disease (MRD). Leukemia 1999, 13:1833-1842.
58. Herrmann A., Hoster E., Zwingers T., et al. Improvement of overall survival in advanced stage mantle cell lymphoma. J Clin Oncol 2009, 27:511-518.
59. Foran J.M., Rohatiner A.Z., Cunningham D., et al. European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma, immunocytoma, and small B-cell lymphocytic lymphoma. J Clin Oncol 2000, 18:317-324.
60. Howard O.M., Gribben J.G., Neuberg D.S., et al. Rituximab and CHOP induction therapy for newly diagnosed mantle-cell lymphoma: molecular complete responses are not predictive of progression-free survival. J Clin Oncol 2002, 20:1288-1294.
61. Lenz G., Dreyling M., Hoster E., et al. Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: results of a prospective randomized trial of the German Low Grade Lymphoma Study Group (GLSG). J Clin Oncol 2005, 23:1984-1992.
62. Ladetto M., De Marco F., Benedetti F., et al. Prospective, multicenter randomized GITMO/IIL trial comparing intensive (R-HDS) versus conventional (CHOP-R) chemoimmunotherapy in high-risk follicular lymphoma at diagnosis: the superior disease control of R-HDS does not translate into an overall survival advantage. Blood 2008, 111:4004-4013.
63. Hiddemann W., Unterhalt M., Herrmann R., et al. Mantle-cell lymphomas have more widespread disease and a slower response to chemotherapy compared with follicle-center lymphomas: results of a prospective comparative analysis of the German Low-Grade Lymphoma Study Group. J Clin Oncol 1998, 16:1922-1930.
64. Corradini P., Ladetto M., Zallio F., et al. Long-term follow-up of indolent lymphoma patients treated with high-dose sequential chemotherapy and autografting: evidence that durable molecular and clinical remission frequently can be attained only in follicular subtypes. J Clin Oncol 2004, 22:1460-1468.
65. Ladetto M., Corradini P., Vallet S., et al. High rate of clinical and molecular remissions in follicular lymphoma patients receiving high-dose sequential chemotherapy and autografting at diagnosis: a multicenter, prospective study by the Gruppo Italiano Trapianto Midollo Osseo (GITMO). Blood 2002, 100:1559-1565.
66. Corradini P., Voena C., Astolfi M., et al. High-dose sequential chemoradiotherapy in multiple myeloma: residual tumor cells are detectable in bone marrow and peripheral blood cell harvests and after autografting. Blood 1995, 85:1596-1602.
67. Corradini P., Voena C., Tarella C., et al. Molecular and clinical remissions in multiple myeloma: role of autologous and allogeneic transplantation of hematopoietic cells. J Clin Oncol 1999, 17:208-215.
68. Martinelli G., Terragna C., Zamagni E., et al. Molecular remission after allogeneic or autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin Oncol 2000, 18:2273-2281.
69. Friedberg J.W., Kim H., Li S., et al. Ex vivo B cell depletion using the Eligix B cell SC system and autologous peripheral blood stem cell transplantation in patients with follicular non-Hodgkin's lymphoma. Bone Marrow Transplant 2003, 32:681-686.
70. Corradini P., Astolfi M., Cherasco C., et al. Molecular monitoring of minimal residual disease in follicular and mantle cell non-Hodgkin's lymphomas treated with high-dose chemotherapy and peripheral blood progenitor cell autografting. Blood 1997, 89:724-731.
71. Jacquy C., Lambert F., Soree A., et al. Peripheral blood stem cell contamination in mantle cell non-Hodgkin lymphoma: the case for purging?. Bone Marrow Transplant 1999, 23:681-686.
72. Tarella C., Corradini P., Astolfi M., et al. Negative immunomagnetic ex vivo purging combined with high-dose chemotherapy with peripheral blood progenitor cell autograft in follicular lymphoma patients: evidence for long-term clinical and molecular remissions. Leukemia 1999, 13:1456-1462.
73. Magni M., Di Nicola M., Devizzi L., et al. Successful in vivo purging of CD34-containing peripheral blood harvests in mantle cell and indolent lymphoma: evidence for a role of both chemotherapy and rituximab infusion. Blood 2000, 96:864-869.
74. Gianni A.M., Magni M., Martelli M., et al. Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen). Blood 2003, 102:749-755.
75. Pott C., Hoster E., Beldjord K., et al. R-CHOP/R-DHAP prior to autologous stem cell transplantation induces higher rates of molecular remission than R-CHOP in younger patients with MCL: results of the MCL younger intergroup trial of the European MCL Network [abstract 965]. Blood 2010, 116.
76. Khouri I.F., Lee M.S., Romaguera J., et al. Allogeneic hematopoietic transplantation for mantle-cell lymphoma: molecular remissions and evidence of graft-versus-malignancy. Ann Oncol 1999, 10:1293-1299.
77. Ladetto M., Magni M., Pagliano G., et al. Rituximab induces effective clearance of minimal residual disease in molecular relapses of mantle cell lymphoma [abstract]. Biol Blood Marrow Transplant 2006, 12:1270-1276.
78. Andersen N.S., Pedersen L.B., Laurell A., et al. Pre-emptive treatment with rituximab of molecular relapse after autologous stem cell transplantation in mantle cell lymphoma. J Clin Oncol 2009, 27:4365-4370.
79. Bertoni F., Roggero E., Luscieti P., et al. Clonality assessment in blood of patients with mantle cell lymphoma. Leuk Lymphoma 1999, 32:375-379.
80. Ferrer A., Salaverria I., Bosch F., et al. Leukemic involvement is a common feature in mantle cell lymphoma. Cancer 2007, 109:2473-2480.
81. Dreger P., Rieger M., Seyfarth B., et al. Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome. Haematologica 2007, 92:42-49.